الفهرس 
CTCs and Pathogenesis of Metastasis
Adnatest (AdnaGen AG)Only 14 pages are availabe for public view
 |  | from | 213 |  |  |
| | | from | 213 | | |
Abstract
Summary
This study was carried out at Clinical Oncology Department and Centre of Excellence for Cancer Research (CECR), Tanta University Hospitals, Tanta, Egypt and Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (ISRT), Meldola, Italy from February 2014 to December 2018. Seventy five patients with nonmetastatic breast cancer were enrolled in this study.
In this study, the median age was 58 year age ranged from 33 to 74 years (with mean age of 57.3±9.5 years). According to the baseline CTCs count, patients were classified into two groups:
group I (the patients who had no CTCs): 53 patients (70.7%)
group II (the patients who had ≥ one CTC): 22 patients (29.3%).
Baseline CTCs count was positive in 22 (29.3%) patients out of 75 patients. On performing the post treatment CTCs count, it was positive in 16 (21.3%) patients.
Among the 22 patients with positive baseline CTCs count, 10 (45.5%) of them remained positive while 12 (54.5%) had negative CTCs count in the post treatment CTCs specimens. While, baseline CTCs count was negative in 53 (70.7%) patients out of 75 patients. On performing the post treatment CTCs count, 47 (88.7%) of them remained negative while in 6 (11.3%) CTCs count became positive.
As regards DFS, the median time for relapse was 33 months (ranged from 20 to 43).